DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2015/0374641 A1 KM Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2015/0374641 A1 KM Et Al US 20150374641A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0374641 A1 KM et al. (43) Pub. Date: Dec. 31, 2015 (54) FILM-FORMING PHARMACEUTICAL Publication Classification COMPOSITION FOR WOUND HEALING AND METHOD FOR PREPARING THE SAME (51) Int. Cl. A69/70 (2006.01) A619/00 (2006.01) (71) Applicant: DONG-A PHARMACEUTICAL CO., A647/36 (2006.01) LTD, Dongdaemun-gu, Seoul (KR) A638/2 (2006.01) (72) Inventors: Soon Hoe KIM, Gyeonggi-do (KR); Mi A613 L/567 (2006.01) (52) U.S. Cl. Won SON, Gyeonggi-do (KR); Sun CPC ............... A61 K9/7015 (2013.01); A61K 38/12 Woo JANG, Seoul (KR); Joon Ho JUN, (2013.01); A61 K3I/567 (2013.01); A61 K Gyeonggi-do (KR); Sang Dug HAN, 47/36 (2013.01); A61 K9/0014 (2013.01) Gyeonggi-do (KR); Sung Rak CHOI, Incheon (KR); Dae Hwan KIM, (57) ABSTRACT Gyeonggi-do (KR); Yong Sung SOHN, The present invention relates to a pharmaceutical composi Seoul (KR); Yong Sam KWON, tion for forming a film directly on a wound to accelerate Gyeonggi-do (KR) wound healing, a use for the same, a treatment method using the same, and a method for preparing the same. The film forming composition according to the present invention (21) Appl. No.: 14/765,318 forms a film directly on the wound to increase the adhesion to the wound. The formed thin hydrophilic film protects the (22) PCT Filed: Feb. 11, 2014 wound surface to prevent infection of the wound surface, retains the physiologically active Substance useful for wound (86). PCT No.: PCT/KR2O14/OO1103 healing on the wound Surface to promote the wound healing, S371 (c)(1), and allow drugs to be continuously delivered to the wound (2) Date: Jul. 31, 2015 Surface. Therefore, the composition according to the present invention has excellent wound healing effect and has excel (30) Foreign Application Priority Data lent usability as it is notabsorbed into clothing, bandage, etc., thus effectively replacing conventional gel or ointment for Feb. 13, 2013 (KR) ........................ 10-2013-OO154OO mations for delivering physiologically active Substances. Patent Application Publication Dec. 31, 2015 US 2015/0374,641 A1 Fig. 1 N s : N sa : 3. 8 g 30 . 8 20 - o : : 10 - o O crococ cococco occer acres occessorW -oc Non-Treated Example. Exarpei3 Tyrasur Ficidin Group N: P-3G. 5 as E-Fest result compared to non-treated group T: PKO. G5 as 'F-'Fest result compared to Tyrosur-treated group F: P-40.05 as T-Fest result compared to Fucidin-treated group Fig. 2) --- cro-e-r-in-a-sur-root-out-o-o-ram . Non-rested 40 me . Tyscrurs as a Fuciding an Execipie 1) i SO 40 20 : 0 - - - - - ------------------------ a-- a---------------------- 2 3 4. s 7 rootsoeveremonsoreau Time (days) - N: P40. Q.5 as T-Test result coalpared to non-treated group T: PKC. 05 as T-Test result compared to Tyrosur-treated group F: P40.05 as T-Test result compared to Fucidin-treated group US 2015/0374641 A1 Dec. 31, 2015 FILM-FORMING PHARMACEUTICAL myofibroblasts. When the levels of collagen production and COMPOSITION FOR WOUND HEALING AND degradation equalize, the maturation and rearrangement METHOD FOR PREPARING THE SAME phase of wound repair is started. During maturation, type III collagen is gradually replaced with type I collagen, and fibro TECHNICAL FIELD blasts are rearranged and cross-linked, resulting in increased tissue tension. This phase can last for a year or longer as the 0001. The present invention relates to a pharmaceutical wound type. composition for forming a film directly on a wound to accel 0004 Wound treatment methods have been studied for a erate wound healing, a use for the same, a treatment method long time and a variety of products have been sold in the using the same and a method for preparing the same. market. Disinfecting products containing oxygenated water, poVidone-iodine, ethyl alcohol, isopropyl alcohol, etc. used BACKGROUND ART to disinfect the wound Surface and dressing products such as 0002. A wound is a type of injury and can be divided into gauze, bandage, etc. which facilitate hemostasis and protect an open wound where skin is torn, punctured or cut and a the wound Surface to prevent secondary infections, etc. have closed wound Such as a bruise, contusion, etc. caused by blunt been sold. Moreover, products containing antibiotics, such as force. There are various methods for treating wounds. When mupirocin, fusidic acid and salts thereof, tyrothricin, etc., the wound is slight, it is healed naturally only by cleaning; used for a wound that may concern infection or be infected however, when the wound is a serious open wound, it needs from Such wound, or products containing a titrated extract of treatment such as cleaning, disinfection, Suture and dressing. Centella asiatica alone or in combination with steroid or In the case of most clean open wounds, they do not require antibiotics have been sold usually in the form of a gel or antibiotic treatment, but a wound that may be infected with ointment. Representative products include Fucidinr) oint bacteria or an infected wound requires antibiotic treatment. ment, Tyrosur R gel, Madecassol(R), etc. 0003. The wound healing process involves a hemostasis 0005. The use of these gel or ointment formulations has phase including vasoconstriction and hemostatic chain reac the following several problems. Upon application to the tion, an inflammatory phase in which immune-related cells wound, the formulation on the wound Surface is not present are activated, a proliferation phase in which damaged blood for a long time due to external contact with gauze, clothing, vessels are newly formed and fibroblasts are formed, and a etc. Therefore, the drug is not in constant contact with the maturation and rearrangement phase in which disorganized wound surface and thus is not continuously delivered to the collagen fibers are rearranged and cross-linked. When a wound. Moreover, when the wound is exposed to the outside wound occurs, blood comes in contact with collagen to pro through the area from which the drug is removed, the prob mote platelet aggregation and secretion of inflammatory Sub ability of re-infection will increase. Further, the exposed stances. Fibrin and fibronectin are cross-linked to form a sort wound causes the patient to feel pain by other external physi of plug, preventing further blood loss. Within an hour after the cal stimuli. Therefore, many patients use disposable bandage, wound occurs, polymorphonuclear neutrophils arrive at the gauze or bandage in combination with the use of these for wound site and become predominant cells in the wound after mulations to cope with these drawbacks, but it is very incon two days. These neutrophils phagocytize debris and bacteria Venient to replace these dressings for each application. In in the wound. Macrophages are essential for wound healing addition, typical products containing antibiotics alone exhibit and replace polymorphonuclear neutrophils the predominant antibiotic activity in infected wound sites and thus they only cells in the wound by two days after injury. The main role of prevent infection in infected wound sites. However, the effect these macrophages is to phagocytize bacteria and damaged of promoting wound healing that make a Swift recovery is not tissue and they also debride damaged tissue by releasing yet known. proteases. These macrophages also secrete growth factors 0006. Therefore, the present inventors have conducted involved in the proliferation phase after post-wounding, con continuous research to overcome the drawbacks of the above tributing to pushing the wound healing process into the next described preparations. As a result, they invented a wound phase. About two or three days after the wound occurs, fibro healing gel, which is usually in the form of a gel during blasts begin to enter the wound site, marking the onset of the storage and usage, converted into the form of a film upon proliferative phase. Angiogenesis, which is important for this application to a wound site to protect the wound site, continu period, occurs concurrently with fibroblast proliferation ously deliver drugs to the wound site, and is not removed from when endothelial cells migrate to the wound site. Simulta the wound site by clothing, gauze, etc. neously with angiogenesis, fibroblasts begin accumulating in 0007. Several formulations containing pharmaceutical the wound site. Fibroblasts begin to increasing as the inflam ingredients as active ingredients and forming films upon matory phase is ending between two and five days after the application to the skin have been known in the art. Korean wound. Their numbers peak between one and two weeks after Patent No. 0551930, Korean Patent Publication No. 2008 wound. While one of the most important functions of such 0049797 and Korean Patent No. 1996-0009415 disclose com fibroblasts is the production of collagen, the production of positions comprising active Substances as well as hydrophilic collagenase and other factors degrading collagen is also one thickeners, hydrophobic polymers such as octylacrylamide of their functions, and the production occurs more rapidly acrylate copolymer, aminoalkyl methacrylate copolymer, than the degradation in the wound. Granulation tissue con ammonio methacrylate copolymer, ethyl acrylate methyl sists of fibroblasts, inflammatory cells, endothelial cells, new methacrylate, and volatile solvents such as ethanol. However, blood vessels, etc. The formation of granulation tissue in an these compositions are separated with exudates after the for open wound allows the reepithelialization phase to take place, mation of films on the wounds due to the high content of as epithelial cells migrate and form a barrier between the hydrophobic polymers and stimulate the wound Surfaces due wound and the environment. Contraction is a key phase of to the high content of organic solvents and thus these com wound healing and begins as fibroblasts differentiate into positions are not suitable for wound healing.
Load more

Recommended publications
  • Tyrothricin ÂŒ an Underrated Agent for the Treatment of Bacterial Skin
    REVIEW Engelhard Arzneimittel GmbH & Co KG, Niederdorfelden, Germany Tyrothricin – An underrated agent for the treatment of bacterial skin infections and superficial wounds? C. LANG , C. STAIGER Received February 22, 2015, accepted March 23, 2016 Dr. Christopher Lang, Engelhard Arzneimittel GmbH & Co. KG, Herzbergstr. 3, 61138 Niederdorfelden, Germany [email protected] Pharmazie 71:299–305 (2016) doi: 10.1691/ph.2016.6038 The antimicrobial agent tyrothricin is a representative of the group of antimicrobial peptides (AMP). It is produced by Bacillus brevis and consists of tyrocidines and gramicidins. The compound mixture shows activity against bacteria, fungi and some viruses. A very interesting feature of AMPs is the fact, that even in vitro it is almost impossible to induce resistances. Therefore, this class of molecules is discussed as one group that could serve as next generation antibiotics and overcome the increasing problem of bacterial resistances. In daily practice, the application of tyrothricin containing formulations is relatively limited: It is used in sore throat medications and in agents for the healing of infected superficial and small-area wounds. However, due to the broad spectrum anti- microbial activity and the low risk of resistance development it is worth to consider further fields of application. 1. Introduction 2. Structure, production, properties A decade after Alexander Fleming published his findings on Tyrothricin is a mixture of polypeptides, consisting of 50 % - 70 % the antibiotic effect of penicillin in 1929 (Fleming 1929), René tyrocidines and 25 % to 50 % gramicidins (Ph.Eur. 8th edition Dubos discovered tyrothricin, a polypeptide mixture obtained 2014). The group of tyrocidines are basic, cyclic peptides, whereas from Bacillus brevis, which was isolated from soil.
    [Show full text]
  • The Systemic Activity and Phytotoxic Effects of Fungicides Effective Against Certain Cotton Pathogens
    Louisiana State University LSU Digital Commons LSU Historical Dissertations and Theses Graduate School 1970 The ysS temic Activity and Phytotoxic Effects of Fungicides Effective Against Certain Cotton Pathogens. Robert Gene Davis Louisiana State University and Agricultural & Mechanical College Follow this and additional works at: https://digitalcommons.lsu.edu/gradschool_disstheses Recommended Citation Davis, Robert Gene, "The ysS temic Activity and Phytotoxic Effects of Fungicides Effective Against Certain Cotton Pathogens." (1970). LSU Historical Dissertations and Theses. 1776. https://digitalcommons.lsu.edu/gradschool_disstheses/1776 This Dissertation is brought to you for free and open access by the Graduate School at LSU Digital Commons. It has been accepted for inclusion in LSU Historical Dissertations and Theses by an authorized administrator of LSU Digital Commons. For more information, please contact [email protected]. 71-3408 DAVIS, Robert Gene, 1932- THE SYSTEMIC ACTIVITY AND PHYTOTOXIC EFFECTS' OF FUNGICIDES EFFECTIVE AGAINST CERTAIN COTTON PATHOGENS. The Louisiana State University and Agricultural and Mechanical College, Ph.D., 1970 Agriculture, plant pathology University Microfilms, Inc., Ann Arbor, Michigan DISSERTATION HAS BEEN MICROFILMED EXACTLY AS RECEIVED THE SYSTEMIC ACTIVITY AND FHYTOTOXIC EFFECTS OF FUNGICIDES EFFECTIVE AGAINST CERTAIN COTTON PATHOGENS A Dissertation Submitted to the Graduate Faculty of the Louisiana State University and Agricultural and Mechanical College in partial fulfillment of the requirements for the degree of Doctor of Philosophy in The Department of Botany and Plant Pathology by Robert Gene Davis B.S., Mississippi State University, 1953 M.S., Mississippi State University, 1968 May, 1970 ACKNOWLEDGEMENT The contributions to this study by others is recognized and appre­ ciated. Dr. J. A.
    [Show full text]
  • (OTC) Antibiotics in the European Union and Norway, 2012
    Perspective Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012 L Both 1 , R Botgros 2 , M Cavaleri 2 1. Public Health England (PHE), London, United Kingdom 2. Anti-infectives and Vaccines Office, European Medicines Agency (EMA), London, United Kingdom Correspondence: Marco Cavaleri ([email protected]) Citation style for this article: Both L, Botgros R, Cavaleri M. Analysis of licensed over-the-counter (OTC) antibiotics in the European Union and Norway, 2012. Euro Surveill. 2015;20(34):pii=30002. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2015.20.34.30002 Article submitted on 16 September 2014 / accepted on 09 February 2015 / published on 27 August 2015 Antimicrobial resistance is recognised as a growing throughout the EU; however, there are still consider- problem that seriously threatens public health and able differences in Europe due to the different health- requires prompt action. Concerns have therefore been care structures and policies (including the extent of raised about the potential harmful effects of making pharmacist supervision for OTC medicines), reimburse- antibiotics available without prescription. Because of ment policies, and cultural differences of each Member the very serious concerns regarding further spread of State. Therefore, the availability of OTC medicines var- resistance, the over-the-counter (OTC) availability of ies in the EU and products sold as POM in certain coun- antibiotics was analysed here. Topical and systemic tries can be obtained as OTC medicines in others. OTC antibiotics and their indications were determined across 26 European Union (EU) countries and Norway As risk minimisation is an important criterion for some by means of a European survey.
    [Show full text]
  • Tyrothricin Zur Behandlung Von Erkrankungen Im Mund- Und Rachenraum Antrag Auf Unterstellung Unter Die Verschreibungspflicht
    Tyrothricin zur Behandlung von Erkrankungen im Mund- und Rachenraum Antrag auf Unterstellung unter die Verschreibungspflicht 0 Sicherheitsaspekte • 80% aller Halsschmerzerkrankungen sind viral bedingt. • In mehr als in 80% der Erkrankungen - ist eine therapeutische Wirksamkeit von Tyrothricin nicht gegeben. - erfolgt die Anwendung eines Wirkstoffs bei fehlender Indikation. - erfolgt eine Fehlanwendung des Arzneimittels, daher sind maximal Nebenwirkungen für den Patienten möglich. • Eine Risikominimierung einer Tyrothricin-Anwendung für das Individuum und die Gesellschaft ist nur durch eine gezielte Therapieempfehlung durch den Arzt möglich - Beratungspflicht des Apothekers besteht, allerdings keine Diagnosemöglichkeit. - Differenzierung für Patienten hinsichtlich einer viralen oder bakteriellen Infektion ist nicht möglich. - Test zur Differenzierung dürfen nicht in der Apotheke durchgeführt oder an Laien abgegeben werden. • Eine Reihe von EU-Länder hat bereits die Zulassung für Lokalantibiotika bei Halsschmerzen aufgrund eines negativen Nutzen-Risiko-Verhältnisses zurückgezogen. Einige pharmazeutische Unternehmer haben freiwillig die Produkte angepasst oder vom Markt genommen. 1 Sicherheitsaspekte Land neubewertetes Produkt (Wirkstoff) Jahr Begründung aus regulatorischer Sicht Alle topischen Antibiotika Topische Antibiotika (Fusafungin, Bacitracin, Gramicidin, FR (Fusafungine, Bacitracine, 2005 Tyrothricin) wurden wegen ihrer zu AMR führenden Dosierung Gramicidine, Tyrothricine) vom Markt genommen GSK Consumer Healthcare Schweiz AG ersetzte
    [Show full text]
  • Efficacy of a Tyrothricin-Containing Wound Gel in an Abrasive Wound Model for Superficial Wounds
    Original Paper Skin Pharmacol Physiol 2013;26:52–56 Received: July 2, 2012 DOI: 10.1159/000343907 Accepted after revision: September 26, 2012 Published online: November 24, 2012 Efficacy of a Tyrothricin-Containing Wound Gel in an Abrasive Wound Model for Superficial Wounds a b a b a W. Wigger-Alberti M. Stauss-Grabo K. Grigo S. Atiye R. Williams c H.C. Korting a b c bioskin GmbH, Hamburg , Engelhard Arzneimittel GmbH & Co. KG, Niederdorfelden , and Department of Dermatology and Allergology, Ludwig Maximilian University, Munich , Germany Key Words corresponding vehicle resulted in statistically significant im- Tyrothricin ؒ Skin ؒ Superficial wound ؒ Wound healing ؒ proved wound healing with an earlier onset of healing in Abrasive wound model particular. Based on these results obtained using an abrasive wound model, it can be concluded that the addition of tyro- thricin 0.1% to the gel vehicle did not interfere with the im- Abstract proved wound healing seen with the vehicle alone. Background: Topical preparations are a common treatment Copyright © 2012 S. Karger AG, Basel for superficial acute wounds, which at the least do not inter- fere with healing and ideally result in enhanced wound heal- ing irrespective of microbial colonization. Objective: To ex- Introduction amine the effects of a topical antimicrobial gel and its vehicle on the wound healing of standardized, superficial abrasions. There is a high incidence of small, superficial, acute Methods: Thirty-three healthy volunteers were enrolled in wounds which are mainly caused by minor cuts, minor a double-blinded, randomized, intraindividual comparison burn injuries (superficial, second degree) or accidental study.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]
  • OUH Formulary Approved for Use in Breast Surgery
    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).
    [Show full text]
  • Antibiotics Stimulating Or Inhibiting Germination and Growth of Rice
    Proceedings of the Iowa Academy of Science Volume 69 Annual Issue Article 33 1962 Antibiotics Stimulating or Inhibiting Germination and Growth of Rice Robert C. Goss State College of Iowa Let us know how access to this document benefits ouy Copyright ©1962 Iowa Academy of Science, Inc. Follow this and additional works at: https://scholarworks.uni.edu/pias Recommended Citation Goss, Robert C. (1962) "Antibiotics Stimulating or Inhibiting Germination and Growth of Rice," Proceedings of the Iowa Academy of Science, 69(1), 199-204. Available at: https://scholarworks.uni.edu/pias/vol69/iss1/33 This Research is brought to you for free and open access by the Iowa Academy of Science at UNI ScholarWorks. It has been accepted for inclusion in Proceedings of the Iowa Academy of Science by an authorized editor of UNI ScholarWorks. For more information, please contact [email protected]. Goss: Antibiotics Stimulating or Inhibiting Germination and Growth of R 1962] ASCORBATE OXIDATION 199 13. Umbreit, W. W., R. H. Burris and J. F. Stauffer. Manometric tech­ niques. Minneapolis, Minn., Burgess Pub. Co. 1957. 14. White, G. A. Atypical ascorbic acid oxidase of Myrothecium verrucaria. Unpublished Ph.D. Thesis. Ames, Iowa, Library, Iowa State University of Science and Technology. 1959. Antibiotics Stimulating or Inhibiting Germination and Growth of Rice ROBERT C. Goss 1 Abstract. This report is concerned with the effect of anti­ biotics on germination and translocation of native chemicals in the laboratory and on the plant's reaction to certain anti­ biotics used as soil drenches under greenhouse conditions. The seeds treated with antibiotics active against Gram positive organisms were deficient in both carbohydrates and proteins.
    [Show full text]
  • Screening a Library of Chalcone Derivatives for Antibacterial Properties Via Kirby Bauer Disk Diffusion
    Bellarmine University ScholarWorks@Bellarmine Undergraduate Theses Undergraduate Works 4-24-2020 Screening a Library of Chalcone Derivatives for Antibacterial Properties via Kirby Bauer Disk Diffusion Breena Z. Frazier Bellarmine University, [email protected] Follow this and additional works at: https://scholarworks.bellarmine.edu/ugrad_theses Part of the Chemicals and Drugs Commons Recommended Citation Frazier, Breena Z., "Screening a Library of Chalcone Derivatives for Antibacterial Properties via Kirby Bauer Disk Diffusion" (2020). Undergraduate Theses. 44. https://scholarworks.bellarmine.edu/ugrad_theses/44 This Honors Thesis is brought to you for free and open access by the Undergraduate Works at ScholarWorks@Bellarmine. It has been accepted for inclusion in Undergraduate Theses by an authorized administrator of ScholarWorks@Bellarmine. For more information, please contact [email protected], [email protected]. Frazier 1 Screening a Library of Chalcone Derivatives for Antibacterial Properties via Kirby Bauer Disk Diffusion Breena Frazier Spring 2020 A Senior Honors Thesis Presented in Partial Fulfillment of the Requirements of the Bellarmine University Honors Program Advisor: Dr. Amanda Krzysiak Reader: Dr. Savita Chaurasia Reader: Dr. Mary Huff Frazier 2 TABLE OF CONTENTS LIST OF FIGURES ................................................................................................... 4 LIST OF TABLES ..................................................................................................... 4 ABSTRACT ..............................................................................................................
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Treatment of Bovine Mastitis R
    Volume 7 | Issue 2 Article 2 1944 Treatment of Bovine Mastitis R. A. Packer Iowa State College Follow this and additional works at: https://lib.dr.iastate.edu/iowastate_veterinarian Part of the Large or Food Animal and Equine Medicine Commons, and the Veterinary Toxicology and Pharmacology Commons Recommended Citation Packer, R. A. (1944) "Treatment of Bovine Mastitis," Iowa State University Veterinarian: Vol. 7 : Iss. 2 , Article 2. Available at: https://lib.dr.iastate.edu/iowastate_veterinarian/vol7/iss2/2 This Article is brought to you for free and open access by the Journals at Iowa State University Digital Repository. It has been accepted for inclusion in Iowa State University Veterinarian by an authorized editor of Iowa State University Digital Repository. For more information, please contact [email protected]. Treatment of Bovine Mastitis Drugs and their administration R. A. Packer, D.V.M., B.S., M.S.* s POINTED out in the previous ar­ agents other than streptococci it would be A ticle on Mastitis, treatment of mas­ useless to use these in a case of staphylo­ titis! should be accompanied by the initi­ coccic mastitis. Laboratory diagnosis is ation of various sanitary measures. essential for intelligent choice of drugs to Treatment without improvement of the be used. sanitation in milking of the herd is almost 2. The stage and severity of the infec­ certain to be unsatisfactory in the long tion. Some of the drugs are too irritant to run, because of subsequent reinfection of be used in the acute stages of the infec­ treated animals. The treatment should be tion.
    [Show full text]
  • 761 Part 446—Tetracycline Antibiotic Drugs
    Food and Drug Administration, HHS Pt. 446 (c) The batch for neomycin content, PART 446ÐTETRACYCLINE polymyxin B content, pH, and sterility. ANTIBIOTIC DRUGS (ii) Samples required: (a) The neomycin sulfate used in Subpart AÐBulk Drugs making the batch: Ten packages, each containing approximately 300 milli- Sec. grams. 446.10 Chlortetracycline hydrochloride. (b) The polymyxin B sulfate used in 446.10a Sterile chlortetracycline hydro- making the batch: Ten packages, each chloride. 446.15 Demeclocycline. containing approximately 300 milli- 446.16 Demeclocycline hydrochloride. grams 446.20 Doxycycline hyclate. (c) The batch: 446.20a Sterile doxycycline hyclate. (1) For all tests except sterility: A 446.21 Doxycycline monohydrate. minimum of six immediate containers. 446.42 Meclocycline sulfosalicylate. (2) For sterility testing: Twenty im- 446.50 Methacycline hydrochloride. mediate containers, collected at regu- 446.60 Minocycline hydrochloride. lar intervals throughout each filling 446.65 Oxytetracycline. operation. 446.65a Sterile oxytetracycline. 446.66 Oxytetracycline calcium. (b) Tests and methods of assayÐ(1) Po- 446.67 Oxytetracycline hydrochloride. tencyÐ(i) Neomycin content. Proceed as 446.67a Sterile oxytetracycline hydro- directed in § 444.42a(b)(1), except pre- chloride. pare the sample as follows: Remove an 446.75a Sterile rolitetracycline. accurately measured portion and dilute 446.76a Sterile rolitetracycline nitrate. with 0.1M potassium phosphate buffer, 446.80 Tetracycline. pH 8.0, to the proper prescribed ref- 446.81 Tetracycline hydrochloride. erence concentration. The neomycin 446.81a Sterile tetracycline hydrochloride. 446.82 Tetracycline phosphate complex. content is satisfactory if it is not less than 90 percent nor more than 130 per- Subpart BÐOral Dosage Forms cent of the number of milligrams of ne- omycin that it is represented to con- 446.110 Chlortetracycline hydrochloride cap- tain.
    [Show full text]